Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Profound Medical (PROF) EBITDA (2023 - 2025)

Historic EBITDA for Profound Medical (PROF) over the last 3 years, with Q3 2025 value amounting to -$8.8 million.

  • Profound Medical's EBITDA fell 4.56% to -$8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.3 million, marking a year-over-year increase of 4557.05%. This contributed to the annual value of -$30.6 million for FY2024, which is 1069.4% down from last year.
  • According to the latest figures from Q3 2025, Profound Medical's EBITDA is -$8.8 million, which was down 4.56% from -$13.0 million recorded in Q2 2025.
  • In the past 5 years, Profound Medical's EBITDA ranged from a high of $6.8 million in Q1 2023 and a low of -$48.5 million during Q4 2023
  • In the last 3 years, Profound Medical's EBITDA had a median value of -$7.6 million in 2024 and averaged -$8.3 million.
  • The largest annual percentage gain for Profound Medical's EBITDA in the last 5 years was 8573.79% (2024), contrasted with its biggest fall of 23385.67% (2024).
  • Over the past 3 years, Profound Medical's EBITDA (Quarter) stood at -$48.5 million in 2023, then surged by 85.74% to -$6.9 million in 2024, then fell by 27.04% to -$8.8 million in 2025.
  • Its EBITDA stands at -$8.8 million for Q3 2025, versus -$13.0 million for Q2 2025 and -$10.6 million for Q1 2025.